Navigation Links
Researchers identify genes that may help in ovarian cancer diagnosis and prognosis
Date:4/9/2012

Philadelphia, PA, April 9, 2012 Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing. These bimodal genes can define tumor subtypes that have different overall prognoses and respond to different therapeutic regimens. The researchers' results are published in the May issue of The Journal of Molecular Diagnostics.

"We identified a very small set of genes that have the potential to be robust prognostic markers in epithelial ovarian cancer," explains lead investigator Michael B. Datto, MD, PhD. "We also demonstrated the utility of a novel approach, bimodal gene discovery, in identifying clinically relevant expression targets."

Ovarian carcinoma has the highest mortality rate among gynecologic malignancies and is the fifth most common cause of cancer death in women. Prognostic methods for serous carcinomas, the most common type of epithelial ovarian malignancy, remain relatively inaccurate. The majority of patients present with high-grade, late-stage tumors and have an overall poor prognosis. Within this group, however, there is a subset with durable response to chemotherapy, resulting in better survival. There are currently no tests in general use that can distinguish tumors that may be more effectively treated.

Based on early work in breast cancer, Dr. Datto and his colleagues hypothesized that clinically relevant bimodal genes exist in epithelial ovarian cancer. Using a large, publically available ovarian cancer microarray dataset, they applied a previously described biomodal index discovery algorithm to evaluate the expression of all genes across 285 samples. They identified many genes with robust patterns of bimodal expression. They also found that a number of genes with bimodal expression patterns are significantly associated with tumor type and/or overall patient survival. When combined into a single sum survival score, the top survival-significant genes identify a clinically distinct molecular subtype of malignant serous ovarian carcinoma.

"From a clinical testing perspective, genes with a continuous pattern of expression can make difficult testing targets. However, the distinction between 'on' or 'off' expression for a particular bimodal gene is relatively straightforward," says Dr. Datto. "This allows clear-cut decision making boundaries and development of precise, reliable testing methods. Bimodal genes may also be candidates for testing by less quantitative methods such as immunohistochemistry."

Several of the bimodal genes that the researchers identified have known roles in tumorigenesis. "This raises the possibility that we have described molecular switch genes that will not only be relevant in the context of ovarian carcinoma, but across multiple tumor types," Dr. Datto concludes.


'/>"/>
Contact: David Sampson
jmdmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Researchers use game to change how scientists study disease outbreaks
2. Notre Dame researchers using novel method to combat malaria drug resistance
3. BU researchers derive purified lung and thyroid progenitors from embryonic stem cells
4. Researchers report potential for a moderate New England red tide in 2012
5. Tales from the crypt lead researchers to cancer discovery
6. Researchers identify new regulator in allergic diseases
7. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
8. Researchers unravel genetic mechanism of fatty liver disease in obese children
9. Montreal researchers repel mortality in Malian mothers
10. UF researchers look for ways to make an emerging technology safe for environment
11. UCSB researchers to examine the effects of year-old NOAA West Coast Catch Shares program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2020)... ... 08, 2020 , ... Cryo-Cell International’s announcement comes on the ... in the medical field. The face masks will be distributed nationwide to obstetrical ... day to provide healthcare to pregnant women. The delivery of masks is scheduled ...
(Date:6/2/2020)... ... June 02, 2020 , ... ... and solutions provider, today reported that the implementation of browser-based, enterprise label ... 100%, resulting in greater efficiency for global biotechnology company, bioMérieux. , Headquartered ...
(Date:5/28/2020)... and FORT WORTH, Texas (PRWEB) , ... May ... ... stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 ... of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 30, 2020 , ... ... announced that the launch of a new clinical diagnostics immuno-oncology service, ... tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the COVID-19 pandemic impacting ... treatment. In an effort to better understand the cellular responses to COVID-19, the ... dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules on ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... solutions providers, today announced its strong opposition to the recently introduced bicameral ... a blanket ban on most federal use of nearly all biometric and related ...
(Date:6/23/2020)... Fla. (PRWEB) , ... June 23, 2020 , ... ... enabled solutions in complex indoor environments, announced today that Derek Fournier has been ... role of Chairman of the Board, effective immediately. , “DeCurtis Corporation has ...
Breaking Biology Technology: